« Return to News | Awards & Advancement

Synthetic Biologics appoints Carol Reed as senior vice president

Thursday, May 17, 2012 11:12 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic DNA-based therapeutics and disease-modifying medicines for serious illnesses, has appointed Carol Reed, M.D., as senior vice president of clinical & regulatory affairs.

In this position, Reed will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the company's regulatory initiatives. Reed brings over 25 years of experience, in medical practice and in the biotechnology/pharmaceutical sector, including six years with Clinical Data, a biopharmaceutical company that was acquired by Forest Laboratories.

Most recently, Reed served as chief medical officer at Clinical Data from 2005 through 2011, after the company merged with Genaissance Pharmaceuticals, where she had served as vice president of medical affairs since 2003. During her tenure at Clinical Data, Reed was responsible for the design and management of two successful consecutive phase III clinical trials for Viibryd, which is used in the treatment of major depressive disorder in adults. Prior to her time at Genaissance, Reed served as associate medical director in pulmonary medical research at Bayer Pharmaceuticals.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.